Literature DB >> 31122560

Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib.

Bao-Dong Qin1, Xiao-Dong Jiao1, Ke Liu1, Ying Wu1, Yuan-Sheng Zang2.   

Abstract

Entities:  

Year:  2019        PMID： 31122560     DOI： 10.1016/j.jtho.2019.01.032

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

Review 1.  Interstitial Deletions Generating Fusion Genes.

Authors:  Ioannis Panagopoulos; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

2.  Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.

Authors:  Hong Tao; Zhe Liu; Jing Mu; Fei Gai; Zhan Huang; Liang Shi
Journal:  Diagn Pathol       Date:  2022-02-10       Impact factor: 2.644

3.  Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.

Authors:  Xueqian Wu; Weiya Wang; Bingwen Zou; Yanying Li; Xiaojuan Yang; Ning Liu; Qizhi Ma; Xiaoxuan Zhang; Yongsheng Wang; Dan Li
Journal:  Thorac Cancer       Date:  2020-03-24       Impact factor: 3.500
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.